 we report on our second quarter 2019 financial results and provide an update on the status of our two lead compounds, 506 and AB-729. 
 we also provide an update on the status of our ongoing studies on healthy volunteers and in chronic hepatitis b subjects.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7    # 1#2#3    # 1#2#3 # 1#2#3 